Institute of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, 07740 Jena, Germany.
Hum Genet. 2011 Sep;130(3):369-76. doi: 10.1007/s00439-011-1068-8. Epub 2011 Jul 15.
In terms of sample exchange, international collaborations between biobanks, or between biobanks and their research partners, have two important aspects. First, the donors' consent usually implies that the scope and purpose of any sample transfer to third parties is subject to major constraints. Since the legal, ethical and political framework of biobanking may differ substantially, even between countries of comparable jurisdictional systems, general rules for the international sharing of biomaterial are difficult, if not impossible, to define. Issues of uncertainty include the right to transfer the material, the scope of research allowed, and intellectual property rights. Since suitable means of international law enforcement may not be available in the context of biobanking, collaborators are advised to clarify any residual uncertainty by means of bilateral contracts, for example, in the form of material transfer agreements. Second, biobank partners may rightly expect that the biomaterial they receive for further analysis attains a certain level of quality. This implies that a biobank has to implement stringent quality control measures covering, in addition to the material transfer itself, the whole process of material acquisition, transport, pre-analytical handling and storage. Again, it may be advisable for biobank partners to claim contractual warranties for the type and quality of the biomaterial they wish to acquire.
就样本交换而言,生物库之间,或生物库与其研究伙伴之间的国际合作有两个重要方面。首先,捐赠者的同意通常意味着任何向第三方转移样本的范围和目的都受到重大限制。由于生物库的法律、伦理和政治框架可能存在很大差异,即使在司法制度相当的国家之间也是如此,因此,要为生物材料的国际共享制定一般性规则是困难的,如果不是不可能的话。不确定的问题包括转让材料的权利、允许的研究范围和知识产权。由于在生物库背景下可能没有适当的国际法执行手段,因此建议合作者通过双边合同(例如以材料转移协议的形式)来澄清任何剩余的不确定性。其次,生物库合作伙伴可能有理由期望他们收到的用于进一步分析的生物材料达到一定的质量水平。这意味着生物库必须实施严格的质量控制措施,除了材料转移本身外,还涵盖材料采集、运输、分析前处理和储存的整个过程。同样,对于生物库合作伙伴来说,要求对他们希望获得的生物材料的类型和质量提出合同保证可能是明智的。